PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OsoBio Appoints Catherine Buck Director of Manufacturing - Buck has 20-plus years of experience managing pharma and commercial manufacturing - OsoBio.com
OsoBio Appoints Catherine Buck Director of Manufacturing

 

NewswireToday - /newswire/ - Albuquerque, NM, United States, 2014/03/31 - Buck has 20-plus years of experience managing pharma and commercial manufacturing - OsoBio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

OsoBio has appointed Catherine R. Buck director of manufacturing.

In her capacity, Buck is responsible for ensuring that OsoBio’s operations comply with current Good Manufacturing Practices (cGMP) as they apply to the manufacturing of injectable sterile liquid, suspension and lyophilized pharmaceutical products. In addition, she ensures compliance with appropriate U.S. Food and Drug Administration and Drug Enforcement Administration regulations, and directs manufacturing activities to ensure timely, cost-effective and efficient production.

Buck brings to OsoBio more than 20 years of leadership and project management experience within the pharmaceutical, medical device and construction industries. She has managed multiple commercial and clinical pharmaceutical manufacturing plants that generated up to $2.5 billion annually.

“The same continuous improvement expectations that bear on just about every aspect of industrial productivity exist within pharmaceutical manufacturing as well,” said Milton Boyer, president of OsoBio. “We are fortunate to add someone with Catherine’s breadth of experience to lead a manufacturing team that keeps OsoBio competitive without sacrificing our commitment to quality and cGMP compliance.”

Her experience includes the start up, process, equipment and facility validation of a new Amgen manufacturing plant that produced Epogen, ® that company’s highest revenue product. Her work included successfully obtaining FDA approval of automated equipment and software, and preparing for inspection and successfully obtaining FDA approval for commercial production. Buck also has managed manufacturing facility operations for Johnson & Johnson and Siemens.

Buck holds a bachelor’s of science degree in electrical engineering from Tufts University, and has completed the Emerging Leader Program at Columbia University.

OsoBio specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products for the pharmaceutical industry. We offer our clients significant experience and knowledge in late Phase III and commercial products.

In the history of our New Mexico facility, we have produced 250-plus distinct commercial products in every major therapeutic category. The DEA has granted OsoBio registrations for Schedule II-V controlled substances.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OsoBio Appoints Catherine Buck Director of Manufacturing

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kys[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Explorers Vacation Club

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)